Intervention not reported
Retained in naltrexone maintenance treatment or abstinent at 12 weeks ‐ Clonidine comparison · patients with opioid withdrawal
The intervention probably leads to higher retained in naltrexone maintenance treatment or abstinent at 12… (moderate certainty).
1 finding from 1 review
Treatment failure To discharge · newborn infants with opioid withdrawal
1 finding from 1 review
Seizures · newborn infants with opioid withdrawal
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neonatal or infant mortality · newborn infants with opioid withdrawal
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neurodevelopmental disability · newborn infants with opioid withdrawal
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · newborn infants with opioid withdrawal
1 finding from 1 review
Days treatment · newborn infants with opioid withdrawal
1 finding from 1 review
Adverse events (treatment related) To discharge · newborn infants with opioid withdrawal
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to adequate sedation (minutes or as measured by specific validated scales such as the Ramsay Sedation Score) · children undergoing neurodiagnostic procedures
1 finding from 1 review
Sedation duration (minutes) · children undergoing neurodiagnostic procedures
1 finding from 1 review
Number of children with clinical adverse event: drowsiness · children undergoing neurodiagnostic procedures
Chloral hydrate oral (50 mg/kg) probably leads to lower number of children with clinical adverse event: drowsiness compared with clonidine oral (4 μg/kg) (moderate certainty).
1 finding from 1 review
Number of children with clinical adverse event: vertigo · children undergoing neurodiagnostic procedures
Chloral hydrate oral (50 mg/kg) showed no clear difference in number of children with clinical adverse event: vertigo compared with clonidine oral (4 μg/kg) (moderate certainty).
1 finding from 1 review
Mean change in IOP from pre‐LTP within 2 hours · people with glaucoma receiving LTP
1 finding from 1 review
IOP increase of ≥ 5 mmHg between 2 and 24 hours · people with glaucoma receiving LTP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
IOP increase of ≥ 10 mmHg between 2 and 24 hours · people with glaucoma receiving LTP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean change in IOP from pre‐LTP between 2 and 24 hours · people with glaucoma receiving LTP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events during treatment period · people with glaucoma receiving LTP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
IOP increase of ≥ 5 mmHg within 2 hours · people with glaucoma receiving LTP
It is very uncertain whether brimonidine changes IOP increase of ≥ 5 mmHg within 2 hours compared with apraclonidine (very low certainty).
1 finding from 1 review
IOP increase of ≥ 10 mmHg within 2 hours · people with glaucoma receiving LTP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Drop‐out (end of treatment) · patients with opiate dependent adolescents
Buprenorphine showed no clear difference in drop out Number of participants who did not complete the… compared with clonidine (moderate certainty).
1 finding from 1 review